Today, a brief rundown of news from Xenon Pharmaceuticals and Capricor Therapeutics, as well as updates from Pfizer, Regeneron, AbbVie and GSK that you may have missed. Expected readouts in obesity, ...

March 9 (Reuters) - Xenon Pharmaceuticals (XENE.O), opens new tab said on Monday its experimental epilepsy drug met the main goal of showing a statistically significant reduction ‌in focal onset ...

Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more than 50% for some patients as it looks to position itself to become the ...

Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7%. Xenon Pharmaceuticals believes this is the highest such efficacy ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Connecticut-based Braidwell disclosed a sale of 1,779,953 shares of Xenon Pharmaceuticals (NASDAQ:XENE) in its February 17, 2026, SEC filing, an estimated $74.76 million trade based on quarterly ...

Connecticut-based Braidwell sold 1,779,953 Xenon Pharmaceuticals shares in the fourth quarter; the estimated transaction value was $74.76 million based on quarterly average prices. Meanwhile, the ...

We have the 8-letter answer for Xenon, e.g. crossword clue, last seen in the LA Times Crossword January 18, 2026 puzzle. This answer will help you finish the puzzle you’re working on.